Press ReleaseAIMHI_wpuser2024-08-29T11:16:30+00:00

Press Release

Press Release

Celebrating Progress in Cancer Research and Entrepreneurship!

AIMHI_wpuser2024-08-13T06:23:57+00:00September 24, 2021|Press Release|

2021 Women’s Venture Competition Announced Semi-Finalists!

AIMHI_wpuser2024-08-13T06:26:02+00:00July 19, 2021|Press Release|

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

AIMHI_wpuser2024-08-13T06:27:28+00:00June 23, 2021|Press Release|

Making Cancer Patient Clinical Trial Recruitment & Engagement Easier

AIMHI_wpuser2024-08-13T06:28:37+00:00June 9, 2021|Press Release|

Privo Technologies, Inc. to Present Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the Upcoming 2021 ASCO Annual Meeting

AIMHI_wpuser2024-08-13T06:29:36+00:00June 3, 2021|Press Release|

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

AIMHI_wpuser2024-08-13T06:31:59+00:00May 10, 2021|Press Release|

Previous 567 Next

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Address:

5515 Security Lane, Suite 1105
Rockville, MD 20852

Email:

info@aim-hiaccelerator.org

Phone:

1-800-321-CURE (2873)

what we do

Copyright © AIM-HI 2024 All Rights Reserved

AIMhi

AIM-HI Accelerator Fund is a 501(c)(3) tax-exempt nonprofit organization.

Tax ID #: 82-4322538

Copyright © AIM-HI 2024 All Rights Reserved